Investors sold shares of Insmed, Inc. (NASDAQ:INSM) on strength during trading on Tuesday. $88.23 million flowed into the stock on the tick-up and $97.00 million flowed out of the stock on the tick-down, for a money net flow of $8.77 million out of the stock. Of all companies tracked, Insmed had the 35th highest net out-flow for the day. Insmed traded up $13.55 for the day and closed at $25.84

Several brokerages recently weighed in on INSM. BidaskClub downgraded shares of Insmed from a “sell” rating to a “strong sell” rating in a research note on Monday, August 14th. Zacks Investment Research raised shares of Insmed from a “hold” rating to a “buy” rating and set a $19.00 target price for the company in a research note on Wednesday, July 5th. ValuEngine downgraded shares of Insmed from a “hold” rating to a “sell” rating in a research note on Thursday, August 3rd. Leerink Swann boosted their target price on shares of Insmed to $36.00 in a research note on Tuesday. Finally, Citigroup Inc. reissued a “neutral” rating and issued a $17.00 target price (up previously from $14.00) on shares of Insmed in a research note on Sunday, June 11th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $27.00.

The company’s market capitalization is $1.68 billion. The company’s 50-day moving average price is $14.37 and its 200-day moving average price is $16.16.

Insmed (NASDAQ:INSM) last announced its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.72) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.63) by $0.09. On average, analysts forecast that Insmed, Inc. will post ($2.70) earnings per share for the current year.

A number of hedge funds and other institutional investors have recently made changes to their positions in INSM. Teachers Advisors LLC boosted its position in Insmed by 7.3% during the 4th quarter. Teachers Advisors LLC now owns 390,648 shares of the biopharmaceutical company’s stock worth $5,168,000 after acquiring an additional 26,597 shares during the period. Russell Investments Group Ltd. boosted its position in Insmed by 219.7% during the 1st quarter. Russell Investments Group Ltd. now owns 57,926 shares of the biopharmaceutical company’s stock worth $1,014,000 after acquiring an additional 39,805 shares during the period. Bank of New York Mellon Corp boosted its position in Insmed by 4.1% during the 1st quarter. Bank of New York Mellon Corp now owns 314,494 shares of the biopharmaceutical company’s stock worth $5,507,000 after acquiring an additional 12,336 shares during the period. Pictet Asset Management Ltd. boosted its position in Insmed by 97.2% during the 1st quarter. Pictet Asset Management Ltd. now owns 124,543 shares of the biopharmaceutical company’s stock worth $2,181,000 after acquiring an additional 61,400 shares during the period. Finally, Swiss National Bank boosted its position in Insmed by 4.9% during the 1st quarter. Swiss National Bank now owns 96,800 shares of the biopharmaceutical company’s stock worth $1,695,000 after acquiring an additional 4,500 shares during the period. Hedge funds and other institutional investors own 89.64% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This news story was reported by Daily Political and is the property of of Daily Political. If you are accessing this news story on another domain, it was stolen and republished in violation of international copyright and trademark laws. The original version of this news story can be read at https://www.dailypolitical.com/2017/09/05/investors-sell-shares-of-insmed-inc-insm-on-strength-insm.html.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company. The Company operates through development and commercialization of therapies for patients with rare diseases segment. Its lead product candidate is ARIKAYCE, or liposomal amikacin for inhalation (LAI), which is in late-stage development for adult patients with treatment refractory nontuberculous mycobacteria (NTM) lung disease caused by Mycobacterium avium complex (MAC).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.